Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 3/20 | 0.32 |
| ▸ | TYMS | P04818 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21614744 | 0.80 | HDAC1 (0.36) | LOXL2LOXIDO1DAOTYMS | |
| SCHEMBL21614743 | 0.80 | DAO (0.38) | LOXL2LOXIDO1DAOMEN1 | |
| SCHEMBL21614746 | 0.80 | LOXL2 (0.35) | LOXL2LOXIDO1DAOTYMS | |
| SCHEMBL18442638 | 0.79 | PLA2G1B (0.33) | DAOMEN1KMT2A | |
| SCHEMBL21614706 | 0.76 | CYP3A4 (0.46) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL21611937 | 0.76 | LOXL2 (0.38) | LOXL2LOXIDO1DAOTYMS | |
| SCHEMBL21611925 | 0.75 | CYP3A4 (0.41) | LOXL2LOXMEN1KMT2A | |
| SCHEMBL21611938 | 0.74 | LTA4H (0.40) | LOXL2LOX | |
| SCHEMBL21611935 | 0.73 | CYP2C19 (0.45) | LOXL2LOXSYK | |
| SCHEMBL15454013 | 0.73 | LOXL2 (0.46) | LOXL2LOXDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3818045-A1 | PQSR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | LOXL2 4197/4885LOX 4457/4885IDO1 469/4885 |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | LOXL2 4197/4885LOX 4457/4885IDO1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.